Back

Innovent to present Phase 3 CLDN18.2 ADC data at 2026 ESMO meeting

Verifying
  • Innovent will present clinical data for five oncology programs and TYVYT at the 2026 ESMO Annual Meeting.
  • G-HOPE-001 Phase 3 data for IBI343/TAK-921 received Late-Breaking Abstract designation.
  • The ESMO meeting runs from Oct. 23 to Oct. 27, 2026, in Madrid.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.